Business Context and Reporting Period
Company: Incyte Corporation (formerly Incyte Genomics, Inc.)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and six months ended June 30, 2003
Business Overview: Incyte is a drug discovery company utilizing medicinal chemistry and biology to develop novel therapeutics for cancer and inflammatory diseases. The company also markets genomic and proteomic information and intellectual property to pharmaceutical and biotechnology firms. In March 2003, the company changed its name from Incyte Genomics, Inc. to Incyte Corporation.
Key Financial Metrics
| Metric (in thousands) | Three Months Ended June 30, 2003 |
Six Months Ended June 30, 2003 |
Six Months Ended June 30, 2002 |
|---|---|---|---|
| Revenues | $11,036 | $23,545 | $58,073 |
| Net Loss | $(26,900) | $(82,684) | $(30,982) |
| Net Loss Per Share (Basic/Diluted) | $(0.37) | $(1.17) | $(0.46) |
| Research & Development Expenses | $29,870 | $60,056 | $71,460 |
| Selling, General & Admin Expenses | $7,694 | $15,071 | $26,916 |
| Purchased In-Process R&D | $0 | $28,116 | $0 |
| Cash and Cash Equivalents (Balance Sheet) | $22,015 (as of June 30, 2003) | ||
| Marketable Securities | $338,624 (as of June 30, 2003) | ||
| Total Current Assets | $378,553 (as of June 30, 2003) | ||
| Total Liabilities | $233,119 (as of June 30, 2003) | ||
| Convertible Subordinated Notes | $171,823 (as of June 30, 2003) | ||
| Accumulated Deficit | $(487,708) (as of June 30, 2003) |
Material Changes vs. Prior Period
- Revenue Decline: Revenues for the six months ended June 30, 2003, decreased to $23.5 million from $58.1 million in the prior year period. This 60% decline is attributed to a softening market for genomic information, reduced research spending by pharmaceutical customers, and the exit of custom genomics product lines in 2001.
- Increased Net Loss: Net loss for the six months ended June 30, 2003, increased to $82.7 million from $31.0 million in 2002. The widening loss was driven by a $28.1 million charge for purchased in-process research and development (IPRD) related to the Maxia Pharmaceuticals acquisition, alongside continued operating losses.
- Expense Reductions: Despite the IPRD charge, operating expenses excluding IPRD decreased. R&D expenses fell to $60.1 million (from $71.5 million) and SG&A fell to $15.1 million (from $26.9 million) due to restructuring programs initiated in 2002.
- Investment Impairments: The company recorded $2.7 million in impairment charges on long-term investments for the six months ended June 30, 2003, compared to none in the prior year.
Guidance, Outlook, and Risks
- Outlook: Management expects revenues in 2003 to be lower than in the prior year due to market softening. The company anticipates incurring additional losses for the next several years as it expands therapeutic discovery and development programs. It does not expect to generate revenues from therapeutic efforts for several years.
- Liquidity: As of June 30, 2003, the company held $360.6 million in cash, cash equivalents, and marketable securities. Management believes these resources are adequate to satisfy capital needs for at least the next twelve months.
- Acquisition of Maxia Pharmaceuticals: Completed on February 18, 2003, for a total purchase price of approximately $27.4 million (stock and cash). The transaction included a $28.1 million IPRD charge. Former Maxia stockholders are eligible for up to $14.0 million in earn-out payments based on clinical milestones.
- Restructuring: The company continues to execute restructuring plans from 2001 and 2002, involving workforce reductions and facility consolidations. Additional charges of $1.4 million were recorded in the first half of 2003 related to these programs.
- Legal Proceedings: Incyte is engaged in patent litigation with Invitrogen Corporation. Invitrogen sued Incyte for patent infringement in 2001; Incyte filed counterclaims. Proceedings were stayed in June and July 2003 pending related appeals. The company cannot estimate potential losses but expects substantial future legal costs.
- Debt Obligations: The company has $170.3 million in face value of convertible subordinated notes outstanding, due in 2007. Interest payments are significant, and the company has a deficiency of earnings available to cover fixed charges.
Key Facts for Investor Verification
- Revenue Sustainability: Verify the trend of declining database and licensing revenues and the impact of pharmaceutical industry consolidation on future renewals.
- Maxia Integration: Monitor the progress of Maxia Pharmaceuticals' drug candidates toward clinical milestones to assess the potential for earn-out payments and future revenue.
- Therapeutic Pipeline: Assess the timeline and capital requirements for Incyte's internal therapeutic discovery programs, which are expected to increase expenses without near-term revenue.
- Legal Exposure: Track the status of the Invitrogen litigation, as an adverse outcome could result in significant damages or licensing restrictions.
- Cash Burn Rate: Evaluate the $58.4 million net cash used in operating activities for the six-month period against the $360.6 million cash balance to determine runway duration.